[go: up one dir, main page]

MX2013007588A - Comprimido de desintegracion oral. - Google Patents

Comprimido de desintegracion oral.

Info

Publication number
MX2013007588A
MX2013007588A MX2013007588A MX2013007588A MX2013007588A MX 2013007588 A MX2013007588 A MX 2013007588A MX 2013007588 A MX2013007588 A MX 2013007588A MX 2013007588 A MX2013007588 A MX 2013007588A MX 2013007588 A MX2013007588 A MX 2013007588A
Authority
MX
Mexico
Prior art keywords
fine granules
active ingredient
pharmaceutically active
lansoprazole
controlled release
Prior art date
Application number
MX2013007588A
Other languages
English (en)
Inventor
Takayuki Okabe
Shiro Ishii
Yutaka Ebisawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45509604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013007588(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2013007588A publication Critical patent/MX2013007588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un comprimido de desintegración oral obtenido por compresión de gránulos finos que muestran una liberación controlada de lansoprazol y un aditivo, que es capaz de suprimir la rotura de los gránulos finos durante la compresión y puede controlar la liberación de lansoprazol durante un tiempo prolongado y puede mantener una concentración terapéuticamente efectiva durante un tiempo prolongado y muestra una propiedad de desintegración en la cavidad oral. Un comprimido de desintegración oral que contiene (i) gránulos finos que muestran una liberación controlada de un ingrediente farmacéuticamente activo, que contiene gránulos finos con un ingrediente farmacéuticamente activo y una capa de recubrimiento con copolímero de ácido metacrílico/acrilato de metilo/metacrilato de metilo, en donde los gránulos finos que contienen un ingrediente farmacéuticamente activo están recubiertos con más del 80% en peso y no más del 300% en peso del copolímero y (ii) gránulos finos que muestran una liberación controlada de un ingrediente farmacéuticamente activo, que contiene el ingrediente farmacéuticamente activo y una capa de recubrimiento que comprende (a) un copolímero de acrilato de etilo/metacrilato de metilo y (b) uno o varios tipos de polimeros seleccionados del grupo que consiste en copolímero de ácido metacrílico/acrilato de etilo, ftalato de hipromelosa, carboximetiletilcelulosa, acetato ftalato de polivinilo, acetato succinato de hidroxipropilmetilcelu losa y acetato ftalato de celulosa, en donde los gránulos finos (i) y gránulos finos (ii) tienen un tamaño de partícula medio de no más deI 500 µm y el ingrediente farmacéuticamente activo es lansoprazol o una de sus formas ópticamente activos o una de sus sales.
MX2013007588A 2010-12-27 2011-12-26 Comprimido de desintegracion oral. MX2013007588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061427384P 2010-12-27 2010-12-27
PCT/JP2011/080568 WO2012091153A2 (en) 2010-12-27 2011-12-26 Orally disintegrating tablet

Publications (1)

Publication Number Publication Date
MX2013007588A true MX2013007588A (es) 2013-08-09

Family

ID=45509604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007588A MX2013007588A (es) 2010-12-27 2011-12-26 Comprimido de desintegracion oral.

Country Status (24)

Country Link
US (1) US20130273157A1 (es)
EP (1) EP2658530A2 (es)
JP (1) JP2014501224A (es)
KR (1) KR20140007364A (es)
CN (1) CN103402500A (es)
AR (1) AR084610A1 (es)
AU (1) AU2011350396A1 (es)
BR (1) BR112013014875A2 (es)
CA (1) CA2823166C (es)
CL (1) CL2013001793A1 (es)
CO (1) CO6731132A2 (es)
CR (1) CR20130327A (es)
EA (1) EA028217B1 (es)
EC (1) ECSP13012718A (es)
MA (1) MA34768B1 (es)
MX (1) MX2013007588A (es)
PE (1) PE20141115A1 (es)
PH (1) PH12013501391A1 (es)
SG (2) SG190905A1 (es)
TN (1) TN2013000220A1 (es)
TW (1) TW201304823A (es)
UY (1) UY33841A (es)
WO (1) WO2012091153A2 (es)
ZA (1) ZA201304617B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021792B1 (ru) 2008-03-11 2015-09-30 Такеда Фармасьютикал Компани Лимитед Твердый препарат, растворяющийся во рту
AP2014007805A0 (en) 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SG10201911668VA (en) 2014-02-07 2020-01-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MX372682B (es) 2014-11-14 2020-06-18 Gemphire Therapeutics Inc Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
HUE072191T2 (hu) 2015-12-04 2025-10-28 Global Blood Therapeutics Inc A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TW202332423A (zh) * 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
IL269884B2 (en) 2017-04-18 2023-09-01 Gemphire Therapeutics Inc Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use
TW201906599A (zh) * 2017-05-11 2019-02-16 美商珍費爾醫療公司 吉卡賓組成物及其使用方法
SG11202000136YA (en) * 2017-07-10 2020-02-27 Takeda Pharmaceuticals Co Preparation comprising vonoprazan
CN108576205B (zh) * 2018-03-22 2022-01-04 湖北省农业科学院农产品加工与核农技术研究所 一种草莓联合干燥的处理方法
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
JP2919771B2 (ja) 1995-04-17 1999-07-19 佐藤製薬株式会社 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
JPH0948726A (ja) 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd 口腔内速崩壊性製剤およびその製法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
JP3746167B2 (ja) 1998-05-18 2006-02-15 武田薬品工業株式会社 医薬製剤
US7399485B1 (en) 1998-07-28 2008-07-15 Takeda Pharmaceutical Company Limited Rapidly Disintegrable solid preparation
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CA2407208C (en) 2000-04-28 2010-08-17 Takeda Chemical Industries, Ltd. Process for producing optically active sulfoxide derivative
WO2001087874A1 (en) 2000-05-15 2001-11-22 Takeda Chemical Industries, Ltd. Process for producing crystal
EP1337525B8 (en) 2000-12-01 2011-10-05 Takeda Pharmaceutical Company Limited Process for the crystallization of (r)- or (s)-lansoprazole
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
CN101340897A (zh) * 2005-12-20 2009-01-07 特瓦制药工业有限公司 兰索拉唑口腔崩解片剂
EP1837016A3 (en) * 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
US9486446B2 (en) * 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
EA021792B1 (ru) * 2008-03-11 2015-09-30 Такеда Фармасьютикал Компани Лимитед Твердый препарат, растворяющийся во рту
WO2010008569A1 (en) * 2008-07-17 2010-01-21 Barr Laboratories, Inc. Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same

Also Published As

Publication number Publication date
KR20140007364A (ko) 2014-01-17
AU2011350396A1 (en) 2013-07-11
ECSP13012718A (es) 2013-12-31
PH12013501391A1 (en) 2013-08-28
WO2012091153A2 (en) 2012-07-05
BR112013014875A2 (pt) 2016-10-18
EA028217B1 (ru) 2017-10-31
CA2823166A1 (en) 2012-07-05
AR084610A1 (es) 2013-05-29
US20130273157A1 (en) 2013-10-17
CN103402500A (zh) 2013-11-20
TW201304823A (zh) 2013-02-01
EP2658530A2 (en) 2013-11-06
CR20130327A (es) 2013-08-22
WO2012091153A3 (en) 2012-09-07
ZA201304617B (en) 2014-08-27
PE20141115A1 (es) 2014-09-12
CA2823166C (en) 2019-04-09
EA201390981A1 (ru) 2014-07-30
SG10201602311XA (en) 2016-04-28
UY33841A (es) 2012-07-31
CL2013001793A1 (es) 2013-12-06
JP2014501224A (ja) 2014-01-20
SG190905A1 (en) 2013-07-31
CO6731132A2 (es) 2013-08-15
TN2013000220A1 (en) 2014-11-10
MA34768B1 (fr) 2013-12-03

Similar Documents

Publication Publication Date Title
TN2013000220A1 (en) Orally disintegrating tablet
JP2010270128A5 (es)
CA2797812A1 (en) Enteric tablet
NZ591688A (en) Dosage form comprising time-pulsatile release beads
RU2015110824A (ru) Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола
JP2019147832A5 (es)
NZ588499A (en) Controlled-release particles with core comprising a weakly basic drug and a controlled-release coating
PE20091620A1 (es) Preparacion solida de desintegracion oral
NZ595691A (en) Drug delivery composition
CN103784414B (zh) 一种埃索美拉唑肠溶片及其制备方法
JP2014533656A5 (es)
JP2015506359A5 (es)
NZ605601A (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
MX2013006247A (es) Tableta oralmente desintegradora.
WO2009043926A3 (en) Oral fast disintegrating tablets
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
JP2013529637A5 (es)
JP2017532363A5 (es)
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
IL308650B2 (en) Gastro-resistant controlled release oral dosage forms
KR20160010595A (ko) 구강내 붕괴정
NZ599742A (en) Improved oral pharmaceutical solid dosage form
CA2797809A1 (en) Enteric tablet
EP2641594A2 (en) Enteric coated solid pharmaceutical compositions for proton pump inhibitors
AR088844A1 (es) Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal